Lv4
450 积分 2025-02-28 加入
Addition of daratumumab to standard triplet regimens achieved better survival in newly diagnosed multiple myeloma: a systematic review and meta-analysis of randomized controlled trials
1个月前
已完结
Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial
1个月前
已完结
Daratumumab, bortezomib, melphalan, and prednisone versus bortezomib, melphalan, and prednisone alone in transplant-ineligible Asian patients with newly diagnosed multiple myeloma: final analysis of the phase 3 OCTANS Study
1个月前
已完结
Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial
1个月前
已完结
Bortezomib, melphalan, and prednisone with or without daratumumab in transplant-ineligible patients with newly diagnosed multiple myeloma (ALCYONE): final analysis of an open-label, randomised, multicentre, phase 3 trial
1个月前
已完结
Teclistamab, a B-Cell Maturation Antigen × CD3 Bispecific Antibody, in Patients with Relapsed or Refractory Multiple Myeloma (MajesTEC-1)
5个月前
已关闭
2022年第64届美国血液学会（ASH）年会（Poster摘要）
5个月前
已关闭
Outcomes of Venetoclax in Patients with Relapsed or Refractory AL Amyloidosis
5个月前
已关闭
Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
5个月前
已完结
皖公网安备34019202002308
